HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

MHRA

Regulatory intelligence
MHRAsafety guidance84% confidence

Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28

Source: MHRA

Why This Matters

Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to pharmaceutical companies; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

Cadila Pharmaceuticals Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of a batch of Mirtazapine 30mg Film-Coated Tablets distributed in Crescent Pharma Limited livery.

Supporting Context

Therapeutic area
General · AI in Drug Development
Sub-indication
General

Related signal: MHRA Launches AI Sandbox to Enhance Medicines Development and Safety

Source

View source document

Related Signal

Open signal — MHRA Launches AI Sandbox to Enhance Medicines Development and Safety
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.